CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS)
Clinical trials for CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS) explained in plain language.
Never miss a new study
Get alerted when new CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS) trials appear
Sign up with your email to follow new studies for CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Tracking a lifelong treatment for debilitating fever diseases
Disease control Recruiting nowThis study is observing how safe and effective the drug Ilaris is for people already taking it to manage rare hereditary fever conditions and a type of juvenile arthritis. It will follow both children and adults for up to four years in real-world clinical settings. The goal is to…
Matched conditions: CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS)
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Apr 04, 2026 06:51 UTC
-
New drug tested for rare 'Cold Allergy' disease
Disease control Recruiting nowThis early-stage study is testing a new drug called JTE-162 for people with Cryopyrin-Associated Periodic Syndrome (CAPS), a rare genetic inflammatory disease. The study will check if the drug is safe and if it reduces inflammation and symptoms like rash, joint pain, and fever. O…
Matched conditions: CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS)
Phase: PHASE1 • Sponsor: Akros Pharma Inc. • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC